Ver­tex joins Mer­ck, Pfiz­er — re­vamp­ing multi­bil­lion-dol­lar tri­al strat­e­gy as biotech R&D crum­bles

You can add Pfiz­er, Mer­ck and — as we found out Fri­day morn­ing — Ver­tex to the grow­ing list of phar­ma gi­ants hit­ting the pause but­ton on a range of clin­i­cal tri­als. But not every­one in R&D is get­ting a red light.

Ver­tex says that it’s do­ing its best to keep work­ing its pipeline strat­e­gy, com­ing up with a plan “to en­able vir­tu­al clin­ic vis­its and home de­liv­ery of study drug to en­sure study con­ti­nu­ity and med­ical mon­i­tor­ing, and to fa­cil­i­tate study pro­ce­dures.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.